8-K: Black Diamond Therapeutics Licenses Oncology Asset BDTX-4933 to Servier for Potential $780 Million

Black Diamond Therapeutics grants Servier Pharmaceuticals a worldwide license to develop and commercialize BDTX-4933, a small molecule targeting RAF/RAS-mutant solid tumors, for an upfront payment of $70 million and potential milestone payments up to $710 million.

Summary

• Black Diamond Therapeutics has entered into a license agreement with Servier Pharmaceuticals for the development and commercialization of BDTX-4933.
• Servier will lead development and commercialization efforts globally, focusing on indications like non-small cell lung cancer and other solid tumors.
• Black Diamond will receive an upfront payment of $70 million.
• The company is eligible for up to $710 million in development and commercial sales milestone payments.
• Additionally, Black Diamond will receive tiered royalties based on global net sales of BDTX-4933.
• The agreement continues until the expiration of the last royalty term for the product in the applicable country, unless terminated earlier due to breach or other customary provisions.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the licensing agreement with Servier, the potential for significant milestone payments and royalties, and the extension of the company's cash runway. The partnership validates Black Diamond's technology and provides resources for continued development of its pipeline.

Positives

• The licensing agreement provides Black Diamond with a significant upfront payment of $70 million.
• The potential for $710 million in milestone payments and tiered royalties offers substantial future revenue opportunities.
• Partnering with Servier, a global pharmaceutical group with expertise in oncology, de-risks the development and commercialization of BDTX-4933.
• The deal extends Black Diamond's cash runway into Q4 2027.
• BDTX-4933 targets a significant unmet need in RAF/RAS-mutant solid tumors, including non-small cell lung cancer.

Negatives

• Black Diamond is relinquishing control over the development and commercialization of BDTX-4933 to Servier.
• The receipt of milestone payments and royalties is contingent on the successful development and commercialization of BDTX-4933 by Servier, which is not guaranteed.
• The company is reliant on Servier's expertise and execution for the success of BDTX-4933.

Risks

• The development of BDTX-4933 may face challenges, including clinical trial failures or regulatory hurdles.
• Servier may not successfully commercialize BDTX-4933, leading to lower-than-expected milestone payments and royalties.
• The License Agreement is subject to termination under certain conditions, such as material breach by either party.
• Competition from other therapies targeting RAF/RAS-mutant solid tumors could impact the commercial success of BDTX-4933.

Future Outlook

Black Diamond Therapeutics anticipates continued development of BDTX-1535 in NSCLC and GBM, with key milestones including initial Phase 2 data in Q4 2025 and potential FDA feedback on the approval pathway. The company also expects initial Phase 0/1b data in newly diagnosed GBM patients in Q2 2026. The Servier partnership provides financial resources to extend the cash runway into Q4 2027.

Management Comments

• Claude Bertrand, Executive Vice-President of R&D at Servier, stated that the partnership to develop BDTX-4933 is an important opportunity in targeted cancer therapies.
• Mark Velleca, M.D., Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics, said that Servier's commitment to innovation and deep expertise in oncology make it an ideal partner for Black Diamond.

Industry Context

This licensing agreement reflects the ongoing trend in the pharmaceutical industry towards strategic collaborations to develop and commercialize promising oncology assets. Servier's focus on targeted cancer therapies and Black Diamond's expertise in MasterKey therapies create a synergistic partnership with the potential to address unmet medical needs in RAF/RAS-mutant solid tumors.

Comparison to Industry Standards

• Licensing agreements in the oncology space often involve upfront payments, milestone payments, and royalties, similar to the structure of this deal.
• The total potential value of $780 million is within the range of other licensing agreements for Phase 1 assets in oncology, although the specific terms vary depending on the target, stage of development, and market potential.
• Companies like Relay Therapeutics and Revolution Medicines are also focused on developing targeted therapies for cancer, and their deals could be used as benchmarks for comparison.
• The tiered royalty structure is a common feature in pharmaceutical licensing agreements, with royalty rates typically ranging from single-digit to low-double-digit percentages of net sales.

Stakeholder Impact

• Shareholders: The licensing agreement is likely to be viewed positively by shareholders, as it provides financial resources and validation of the company's technology.
• Employees: The partnership with Servier could create new opportunities for employees involved in the development of BDTX-4933.
• Patients: The development of BDTX-4933 has the potential to provide a new treatment option for patients with RAF/RAS-mutant solid tumors.
• Servier: The licensing agreement allows Servier to expand its oncology pipeline and strengthen its position in targeted cancer therapies.

Next Steps

• Servier will lead the development and commercialization of BDTX-4933.
• Black Diamond will file the License Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025.
• Black Diamond anticipates initial Phase 2 results and FDA feedback on approval pathway for BDTX-1535 in Q4 2025.
• Black Diamond expects initial Phase 0/1b data in newly diagnosed GBM patients in Q2 2026.

Key Dates